You are here

  • Home
  • Archive
  • Volume 12, Issue 6
  • Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma

 

Online download statistics by month:

Online download statistics by month: June 2024 to July 2025

AbstractFullPdf
Jun 2024454510
Jul 2024808818248
Aug 202426727477
Sep 202411711863
Oct 2024929262
Nov 2024838452
Dec 202411511646
Jan 2025899148
Feb 202526126138
Mar 2025979762
Apr 202510810866
May 2025848547
Jun 2025414131
Jul 2025440
Total22112234850